Zydus receives tentative approval from USFDA for Ibrutinib tablets

Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad

Dr Reddy's Laboratories reports 2% rise in Q1 net profit to Rs. 1,418 Cr

Revenue increased 11.4 per cent to Rs. 8,545 crore

Pfizer completes licensing agreement with 3SBio to expand oncology portfolio

3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio

Akums launches high-strength Paracetamol oral suspension 500mg/5ml

Akums bridges the long-standing gap between paediatric syrups and conventional tablet formats

Lonza reports 19% growth in sales in H1

Upgrades 2025 full-year CDMO sales and margin outlook

AstraZeneca plans to invest $50 billion in US by 2030

Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US

Roche updates on sBLA for Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma

Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population

Sarepta refuses to comply with FDA request to stop shipping gene therapy Elevidys

FDA requests Sarepta Therapeutics to suspend distribution of Elevidys and places clinical trials on hold for multiple gene therapy products following 3 deaths

ImCheck’s ICT01 receives FDA ODD for treatment of acute myeloid leukemia

Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials

Biocon Biologics expands diabetes portfolio with FDA approval of Kirsty